Product Images Fesoterodine Fumarate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Fesoterodine Fumarate NDC 65162-370 by Amneal Pharmaceuticals Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Structural Fomula - fesoterodine fumarate extended release tablets 1
figure 1 - fesoterodine fumarate extended release tablets 2
The text describes a figure showing the change in the number of urinations per 24 hours in a study with three groups: a placebo group, a group taking fesoterodine fumarate 4mg, and a group taking fesoterodine fumarate 8mg. The figure tracks the change over a period of 12 weeks. The title of the figure is "Change in Number of Micturitions per 24 h (Study 1)". The description mentions "Mean change from baseline", but no values are provided.*
figure 2 - fesoterodine fumarate extended release tablets 3
The text describes a graph that shows the change in urge incontinence episodes per 24 hours in a study which took place across 12 weeks. The graph displays three results: a placebo group of 211 individuals, a group of 199 individuals given Fesoterodine fumarate 4mg, and a group of 223 individuals given Fesoterodine fumarate 8mg. The text also provides a title for the graph and a measurement unit for the y-axis.*
figure 3 - fesoterodine fumarate extended release tablets 4
This is a graph showing the mean change in the number of micturitions per 24 hours over a 12-week period for three groups: placebo (N=266), fesoterodine fumarate 4 mg (N=267), and fesoterodine fumarate 8 mg (N=267). The x-axis shows the weeks while the y-axis shows the change from baseline. No other information is available.*
figure 4 - fesoterodine fumarate extended release tablets 5
The text describes a figure showing the change in urge incontinence episodes per 24 hours over a 12 week period in a study with three groups: a placebo group (N=205), a group taking fesoterodine fumarate 4 mg (N=228), and a group taking fesoterodine fumarate 8 mg (N=218). The x-axis shows the weeks and the y-axis shows the mean change from baseline in urge incontinence episodes per 24 hours.*
4 mg 30 count label - fesoterodine fumarate extended release tablets 6
This text describes a medication with the NDC code 65162-369-03, which comes in the form of an extended-release film-coated tablet containing 4mg of fesoterodine fumarate. The usual dosage and storage instructions are provided alongside a request for pharmacists to dispense the medication with a patient information leaflet and protect it from moisture. The medication is distributed by Amneal Pharmaceuticals LLC.*
8 mg 30 count label - fesoterodine fumarate extended release tablets 7
This is a medication with NDC number 65162-370-03. Each tablet of this medication is extended-release and film-coated containing 8mg of fesoterodine fumarate. The recommended dosage of this medication is available in the accompanying prescribing information. It is suggested to store the tablets at 20 to 25°C (68 to 77°F) with excursions permitted between 15 to 30°C (59 to 86°F). The medication should be protected from moisture. It is distributed by Amneal Pharmaceuticals LLC, located in Bridgewater, NJ. This information is current as of January 2021.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.